Key result
Calcium antagonists serve as heterogeneous therapies for angina, hypertension, and arrhythmias.
Calcium antagonists have diverse therapeutic applications across multiple cardiovascular and non-cardiovascular conditions.
Highlights heterogeneity to guide agent selection; leaves open comparative trials across indications.
Drugs which interfere with the voltage-activated inward displacement of calcium ions into excitable cells, including those of the myocardium, atrial and ventricular nodes, and smooth muscle cells, have become known as calcium antagonists. These drugs are a heterogeneous group, and differ from one another in chemistry, tissue specificity, potency and bioavailability. The prototype of the group is verapamil. Other calcium antagonists are nifedipine and diltiazem. The therapeutic applications of these compounds include the relief of angina pectoris, and the management of hypertension, ischaemic heart disease and, in certain instances, arrhythmias. Calcium antagonists are also useful in the management of oesophageal achalasia, Raynaud's disease, and hypertrophic obstructive cardiomyopathy, and may be of use in premature labour.
No takes yet. Share an insight, caveat, or question.
Winifred G. Nayler (1983) conducted a review in Cardiovascular and other conditions (angina pectoris, hypertension, ischaemic heart disease, arrhythmias). Calcium antagonists (verapamil, nifedipine, diltiazem) was evaluated. Calcium antagonists, including verapamil, nifedipine, and diltiazem, are a heterogeneous group of drugs with therapeutic applications in angina, hypertension, arrhythmias, and other conditions.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: